Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (September 2024)
32 slides from Maia Biotechnology's investor presentation, Sep 10, 2024
Slide 1: MAIA Biotechnology: Telomere Targeting Immunotherapies for Cancer
MAIA BIOTECHNOLOGY TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA September 2024
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS (es) mala NYSE American: MAIA All statements inthis presentation, other than those relating to historical facts, are “forward-looking steternents.” These forward-iooking statements may include, but are not limited to, statements relating to our objectives, plans, and strat
Slide 3: Investment Profile
INVESTMENT PROFILE New science for cancer therapy: dual MOA telomere targeting and immunogenicity. * Lead molecule THIO in clinic; 2nd generation compounds in R&D Phase 2 trial THIO-101 nearing completion: THIO sequenced with CPI in NSCLC. + Unprecedented disease control, response, post-therapy pati
Slide 4: Pipeline and Collaboration Rights
PHASE 1 | PHASE 2 |PHASE3|/ COLLABORATION & RIGHTS Enrollment Worldwide rights Sincs\sipn nplete | owned by MAIA REGENERON oi ca THIO-102 CRC, HCC, SCLC, ST (THIO CPI) planning Worldwide,riehts | owned by MAIA Ph 2/3 Worldwide rights Planning owned by MAIA ents IND bli Enabling Developed in-house fu
Slide 5: Mission and Approach
MISSION AND APPROACH NYSE American: MAIA,
Slide 6: Cancer as the dominant age-related disease
Population aged >80 \ {i — @& expected to triple by 2050 7 (e) Cancer is the most dominant aes ate aa, ; age-related / will be diagnose : 20% will die of it disease
Slide 7: THIO is the only direct telomere targeting anticancer agent in clinical development
rN THIO is the only direct telomere targeting anticancer agent in clinical development
Slide 8: THIO: Novel Mechanisms of Action
THIO — NOVEL MECHANISMS OF ACTION (CORAL NYSE American: MAIA THIO fst) MAIA Immune Checkpoint Inhibitor THIO has a dual MoA: . V © IMFINZI @ Telomere targeting Tumoral octaad (durvalumab) © Immunogenic effect REGENERON | Astazenecd KEYTRUDA " Followed by PD-L1 (pembrolizumab) (tistelizumab) © merck
Slide 9: THIO followed by CPI results in 60% complete response
* THIO followed by CPI results in 60% complete response * Only 2 cycles of therapy were administered on weeks 1 and 2; no further therapy throughout the study * No recurrence after long-term follow- up * Anticancer immune memory has been induced: no cancer after rechallenge with 5x more lung cancer
Slide 10: THIO-101 Trial: Non-Small Cell Lung Cancer
THIO-101 TRIAL NON-SMALL CELL LUNG CANCER NYSE American: MAIA,
Slide 11: Regeneron Clinical Supply Agreement
REGENERON CLINICAL SUPPLY AGREEMENT (i) NYSE MAIA & REGENERON BIOTECHNOLOGY MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo® (cemiplimab) in Advanced Non-Small Cell Lung Cancer a
Slide 12: THIO-101 Trial Design
THIO-101 — TRIAL DESIGN A Multicenter, Open-Label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with LIBTAYO® (cemiplimab) in NSCLC patients RESISTANT TO CHECKPOINT INHIBITORS Part A: Part B: Expansio Safety Efficacy / Safety / Dose Selection Registr
Slide 13: Patients' Survival by Line of Therapy
PATIENTS' SURVIVAL BY LINE OF THERAPY (i) "a!4 NYSE American: MAIA As of 01-Aug-2024, 16 _‘Seeend-Line (All Doses) 45 patients _ Third-Line+ (All Doses): 24 patients patients had survival i Be $ on follow-up above 12 ° ° months: ¥ 7in 2L, 7 ongoing ¥ 9 in 3L, 7 ongoing v 1 patient with 23 cycles of
Slide 14: Treatment in Third-Line
TREATMENT IN THIRD-LINE (Sala NYSE American: MAIA Extended Survival Third Line (All Doses): 20 patients + 20 subjects in 3L completed at least 1 post baseline assessment at time of cut-off + 14/20 (70%) patients crossed 5.8 months OS threshold + 17/20 (85%) crossed 2.5 months PFS threshold Unprecede
Slide 15: Best 3L Results in the 180mg Dose
BEST 3L RESULTS IN THE 180MG DOSE NSCLC-3 - 180mg: * 6/8 (75%) patients crossed 5.8 months OS threshold + 7/8 (88%) crossed 2.5 months PFS threshold Legend ‘Treatment Follow-Up © Stable Disease (So) |B Partial Response (PR) ‘A. Progressive Disease (PO) © Death (© withdrawal © others Third-Line (180m
Slide 16: Expected Efficacy and Current Treatments
EXPECTED EFFICACY AND CURRENT TREATMENTS §$(&)MAIA NYSE American: MAIA Third-Line pe eons) Chemethers rceva? (erlo' Taxotere' NSCLC Libtayo® (cem Py (docetaxel) Population CPI Resistant (3L) CPI Naive (3L) CPI Naive (2L+) CPI Naive (2L) DCR 88% 36% 45% 54% ORR 38% 6% 9% 5.7% 1.9 months PFS 5.5 month
Slide 17: Planned Upcoming Trials
PLANNED UPCOMING TRIALS NYSE American: MAIA,
Slide 18: THIO-102 Trial (Planned)
THIO-102 TRIAL (PLANN A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Anti-PD-1 or Anti-PD-L1 Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 2 Baskets Umbrella Arms Colorectal Cancer (CRC) Hepatocellular Expand Best Carcinoma
Slide 19: THIO followed by CPI results in 100% complete response
* THIO followed by CPI results in 100% complete response = * Only 2 cycles of therapy were rf administered on weeks 11 and 2; no 2 further therapy throughout the study 4 £ + Norecurrence after long-term follow-up 2 * Anticancer immune memory has been induced: no cancer after rechallenge with 10x mor
Slide 20: SCLC & HCC - Orphan Drug Designation
SCLC & HCC - ORPHAN DRUG DESIGNATION (vals NYSE American: MAIA SCLC —eControl —e—Pembro > THIO —e-THIO > Pembro Tumor Volume (mm?) 3 a 3 0 5 10 15 20 25 Days After Tumor Inoculation THIO is synergistic with anti-PD-1 agent Pembrolizumab in Small Cell Lung Carcinoma (H2084) in vivo in humanized murin
Slide 21: Excellent Efficacy in HCC Models
EXCELLENT EFFICACY IN HCC MODELS _~ 600 "E * THIO achieved complete and durable responses in £ Hepatocellular Carcinoma (HCC), the dominant =— 400 histology in primary liver cancer (90%), in in vivo 2 models Ss $ ~ 200 2 100% CR 3 Pd 1 0 0 5 101520 2530354045 Days after tumor inoculation 21
Slide 22: HCC: THIO with Libtayo and Immune Memory
HCC ANT + When combined with immunotherapy checkpoint inhibitor Libtayo®, duration of response was further potentiated + Upon rechallenge with two times more cancer cells and no additional treatment, tumor growth was completely prevented + Administration of THIO alone and in combination with Libtayo
Slide 23: THIO-103 Trial (Planned)
THIO-103 TRIAL (PLANNED) NYSE American: MAIA A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Anti-PD-1 or Anti-PD-L1 Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 3 Baskets SCLC FirstLine ]Mia}es Checkpoint Inhibitor: Expand
Slide 24: Investment Opportunity
INVESTMENT OPPORTUNITY NYSE American: MAIA,
Slide 25: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY (i) “a!4 NYSE American: MAIA =] Goal: New Chemical Entity (NCE) Marketing Exclusivity Ae * THIO has never been previously approved by the FDA for commercialization + Robust exclusivity * US: 7 years; EU, Japan, other markets: 10 years Robust and Growing Patent P
Slide 26: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM (CORAL NYSE American: MAIA <4 Vlad Vitoc, MD, MBA Sergei Gryaznov, PhD Jeffrey Himmelreich, MBA Founder and CEO Chief Scientific Officer Head of Finance * 24+ years in Oncology Pharma/ * 25+ years as Scientist * 20+ years of financial Biotech: Commercial, Medical + Expert
Slide 27: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY Developing agents for the top tumor Checkpoint Inhibitors Market , types markets globally 2023 Sales ($B) NSCLC (#2 WW) HCC Mortality: 1.7M / Sales: $34B Mortality: 0.8M / Sales: $3B 25 25 20 CRC (#2 WW) SCLC Mortality: 1.0M / Sales: $20B Mortality: 0.3M/Sales:$2B 15 1
Slide 28: Peer Market Capitalization Comparison
eee ere Bane ener eS i ‘Bes wale. = oD ae (&j) MAIA iM IRATI, IOVANCE} Bicycle | ARCUS |y BIOTECHNOLOGY Motu rRapentics § BIOTHERAPEUTICS $75.8M | $4.1B $3.0B $1.4B $1.48 $3.8B Market Cap? Market Cap? Market Cap? Market Cap? Market Cap? Market Cap? $3.17/share $58/share $10/share $20.5/share $15.7/s
Slide 29: Multiple Value-Driving Milestones
MULTIPLE VALUE-DRIVING MILESTONES % Major inflection points 2024 | 2025 ] 202 THIO-101 Early PartB PartB PartB Part C PartC Filing for Potential Ph2 Efficacy Efficacy Long-term Full Efficacy Enrollment US Accelerated NSCLC-2+ Update (ASCO) Efficacy Efficacy Update Complete approval Approval in (Biot
Slide 30: Thank You
MAIA BIOTECHNOLOGY THANK YOU Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 Chicago, IL 60606 MAIA NYSE American: MAIA
Slide 31: Appendix
APPENDIX NYSE American: MAIA,
Slide 32: U.S. FDA Granted Orphan Drug Designations to THIO
U.S. FDA GRANTED 3 ORPHAN DRUG DESIGNATIONS TO THIO (3) MAIA NYSE American: MAIA * The FDA’s Orphan Drug Act of 1983 is designed to incentivize the development of therapies that demonstrate promise for the treatment g 3x FDA of rare (orphan) diseases or conditions Fe + Rare disease - affects fewer t
MAIA Biotechnology — Investor Presentation (September 2024) on 6ix